All three doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...